Adam E. Richardson

Adam E. Richardson

Auto-generated profile, based on publicly available information

Adam E. Richardson

AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JGJoseph M. Gumina
Joseph M. Gumina
ARAdam E. Richardson
Adam E. Richardson
MSMahmudul Hasan Shojiv
Mahmudul Hasan Shojiv
ACAntonio E. Chambers
Antonio E. Chambers
SSSiara N. Sandwith
Siara N. Sandwith
RHRobert A Haney
Robert A Haney
G-quadruplexes (G4s) are secondary DNA and RNA structures stabilized by positive cations in a central channel formed by stacked tetrads of Hoogsteen base-paired guanines. G4s form from G-rich sequences across the genome, whose biased distribution in regulatory regions points towards a gene-regulatory role. G4s can themselves be regulated by helicases, such as DHX36 (aliases: G4R1 and RHAU), which possess the necessary activity to resolve these stable structures. G4s have been shown to both positively and negatively regulate gene expression when stabilized by ligands, or through the loss of helicase activity. Using DHX36 knockout Jurkat cell lines, we identified widespread, although often subtle, effects on gene expression that are associated with the presence or number of observed G-quadruplexes in promoters or gene regions. Genes that significantly change their expression, particularly those that show a significant increase in RNA abundance under DHX36 knockout, are associated with a range of cellular functions and processes, including numerous transcription factors and oncogenes, and are linked to several cancers. Our work highlights the direct and indirect role of DHX36 in the transcriptome of T-lymphocyte leukemia cells and the potential for DHX36 dysregulation in cancer.

20 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme that is constitutively activated by stimulation of the B-cell receptor or gain-of-function mutations in upstream components of the signaling pathway, making it an attractive therapeutic target. We discovered a novel small-molecule inhibitor, ABBV-MALT1, that potently shuts down B-cell signaling selectively in ABC-DLBCL preclinical models leading to potent cell growth and xenograft inhibition. We also identified a rational combination partner for ABBV-MALT1 in the BCL2 inhibitor, venetoclax, which when combined significantly synergizes to elicit deep and durable responses in preclinical models. This work highlights the potential of ABBV-MALT1 monotherapy and combination with venetoclax as effective treatment options for patients with ABC-DLBCL.

17 June 2026
Verified
Other
Open access
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Whole proteomic analysis of ABBV-MALT1 in OCI-LY3

2 July 2024
Verified
Other
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts

2 July 2024
Verified
Other
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Whole proteomic analysis of ABBV-MALT1 in OCI-LY3

2 July 2024
Verified
Other
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts